Financials in USD. Standardized financial statements.
A compact view of how Mereo BioPharma Group plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $500,000 | $0 | $10.00M | $0 | $49.21M | $0 | $0 | $0 | -$3.29M | $0 |
| Revenue Growth? | 0.0% | -100.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | +100.0% | 0.0% | 0.0% |
| Cost of Revenue? | $133,000 | $0 | $2.57M | -$257,442 | $24.17M | $2.05M | $2.01M | $22.70M | $34.61M | $24.56M |
| Gross Profit? | $367,000 | $0 | $7.43M | $257,442 | $25.04M | -$2.05M | -$2.01M | -$22.70M | -$37.89M | -$24.56M |
| Gross Margin? | +73.4% | 0.0% | +74.3% | 0.0% | +50.9% | 0.0% | 0.0% | 0.0% | +1153.4% | 0.0% |
| Operating Expenses? | $38.62M | $47.36M | $35.84M | $53.92M | $53.30M | $46.13M | $48.40M | $12.50M | $10.70M | $11.62M |
| Operating Income? | -$38.26M | -$47.36M | -$28.42M | -$53.67M | -$28.26M | -$48.18M | -$50.41M | -$35.21M | -$45.30M | -$36.18M |
| EBITDA? | -$40.47M | -$40.80M | -$26.06M | -$39.98M | $25.49M | -$203.41M | -$44.57M | -$34.86M | -$44.44M | -$38.41M |
| Income Before Tax | -$41.88M | -$43.25M | -$30.00M | -$44.46M | $19.22M | -$213.45M | -$52.46M | -$37.31M | -$46.95M | -$33.72M |
| Income Tax Expense | $0 | $0 | -$532,000 | -$2.34M | $2.05M | -$3.62M | -$8.00M | -$5.28M | -$8.15M | -$5.33M |
| Net Income? | -$41.88M | -$43.25M | -$29.47M | -$42.12M | $17.17M | -$209.83M | -$44.45M | -$32.03M | -$38.80M | -$28.39M |
| EPS? | $-0.26 | $-0.29 | $-1100.22 | $-1750.35 | $749.65 | $-16503.30 | $-12902.58 | $-14352.87 | $-19003.80 | $-19553.91 |
| Diluted EPS? | $-0.26 | $-0.29 | $-1100.22 | $-1750.35 | $749.65 | $-16503.30 | $-12902.58 | $-14352.87 | $-19003.80 | $-19553.91 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality